Molecules · 2015 · 22 citations · 39 references
Life SciencesBiochemistryMedicinal ChemistryDrug DesignDrug DiscoveryEnzymologyAllosteric Drug DesignAllosteric Modulator DesignAllosteric RegulationEnzyme InhibitionExtracellular Matrix GlycansAllosteric InhibitionAllosteric Inhibition MechanismsAllosteric MechanismsGlycosaminoglycan StructureInhibitor SelectivityPlasmin ActivityPlasminogen ActivatorsRegulation By Serine Protease Inhibitors
Plasmin, a key serine protease, plays a major role in clot lysis and extracellular matrix remodeling. Heparin, a natural polydisperse sulfated glycosaminoglycan, is known to allosterically modulate plasmin activity. No small allosteric inhibitor of plasmin has been discovered to date. We screened an in-house library of 55 sulfated, small glycosaminoglycan mimetics based on nine distinct scaffolds and varying number and positions of sulfate groups to discover several promising hits. Of these, a pentasulfated flavonoid-quinazolinone dimer 32 was found to be the most potent sulfated small inhibitor of plasmin (IC50 = 45 μM, efficacy = 100%). Michaelis-Menten kinetic studies revealed an allosteric inhibition of plasmin by these inhibitors. Studies also indicated that the most potent inhibitors are selective for plasmin over thrombin and factor Xa, two serine proteases in coagulation cascade. Interestingly, different inhibitors exhibited different levels of efficacy (40%-100%), an observation alluding to the unique advantage offered by an allosteric process. Overall, our work presents the first small, synthetic allosteric plasmin inhibitors for further rational design.
39
The binding of low molecular weight heparin to hemostatic enzymes.
Robert E. Jordan, G.M. Oosta, W.T. Gardner et al. · Journal of Biological Chemistry · 1980 · 108 citations · Full text